Immune complex formation impairs the elimination of solutes from the brain: implications for immunotherapy in Alzheimer’s disease

Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction

(2012) Jessica L. Teeling et al.   ACTA NEUROPATHOLOGICA

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

(2012) Bengt Winblad et al.   LANCET NEUROLOGY

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab

(2011) Christopher Carlson et al.   Alzheimers & Dementia

Review: Sporadic cerebral amyloid angiopathy

(2010) J. Attems et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Decreased Clearance of CNS  -Amyloid in Alzheimer's Disease

(2010) K. G. Mawuenyega et al.   SCIENCE

Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy

(2009) Roy O. Weller et al.   ACTA NEUROPATHOLOGICA

Editorial [Hot Topic: Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part II (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]

(2009) David Cribbs et al.   CNS & Neurological Disorders-Drug Targets

Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease

(2009) R. Deane et al.   CNS & Neurological Disorders-Drug Targets

Complement activation and inhibition: a delicate balance

(2009) A.P. Sjöberg et al.   TRENDS IN IMMUNOLOGY